JP2008538215A - サーチュイン活性化剤による眼障害の処置 - Google Patents

サーチュイン活性化剤による眼障害の処置 Download PDF

Info

Publication number
JP2008538215A
JP2008538215A JP2008504422A JP2008504422A JP2008538215A JP 2008538215 A JP2008538215 A JP 2008538215A JP 2008504422 A JP2008504422 A JP 2008504422A JP 2008504422 A JP2008504422 A JP 2008504422A JP 2008538215 A JP2008538215 A JP 2008538215A
Authority
JP
Japan
Prior art keywords
formula
compound
further embodiment
attendant definitions
sirtuin activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538215A5 (enExample
Inventor
クリストファー アール． ウエストファール，
ミシェル ディップ，
マイケル ミルバーン，
Original Assignee
サートリス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サートリス ファーマシューティカルズ， インコーポレイテッド filed Critical サートリス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2008538215A publication Critical patent/JP2008538215A/ja
Publication of JP2008538215A5 publication Critical patent/JP2008538215A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008504422A 2005-03-30 2006-03-30 サーチュイン活性化剤による眼障害の処置 Pending JP2008538215A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66717905P 2005-03-30 2005-03-30
US68425205P 2005-05-25 2005-05-25
US11/374,278 US20070014833A1 (en) 2005-03-30 2005-10-28 Treatment of eye disorders with sirtuin modulators
PCT/US2006/011930 WO2006105403A2 (en) 2005-03-30 2006-03-30 Treatment of eye disorders with sirtuin modulators

Publications (2)

Publication Number Publication Date
JP2008538215A true JP2008538215A (ja) 2008-10-16
JP2008538215A5 JP2008538215A5 (enExample) 2009-04-09

Family

ID=37054169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504422A Pending JP2008538215A (ja) 2005-03-30 2006-03-30 サーチュイン活性化剤による眼障害の処置

Country Status (6)

Country Link
US (1) US20070014833A1 (enExample)
EP (1) EP1863462A2 (enExample)
JP (1) JP2008538215A (enExample)
AU (1) AU2006230478B2 (enExample)
CA (1) CA2603009A1 (enExample)
WO (1) WO2006105403A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542296A (ja) * 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置
JP2013237618A (ja) * 2012-05-11 2013-11-28 Hinoki Shinyaku Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤
KR20140048212A (ko) 2011-06-29 2014-04-23 가부시키가이샤 롯데 눈 피로 억제 조성물 및 그것을 함유하는 음식품
JP2015187141A (ja) * 2005-07-01 2015-10-29 プレジデント アンド フェローズ オブ ハーバード カレッジ 肥満及びインシュリン耐性障害を治療又は予防するための組成物
JP2016050172A (ja) * 2014-08-28 2016-04-11 学校法人昭和大学 新規スチルベン誘導体
WO2016171152A1 (ja) * 2015-04-20 2016-10-27 学校法人 慶應義塾 角膜障害の治療剤、改善剤または予防剤
JPWO2016031869A1 (ja) * 2014-08-28 2017-06-15 学校法人慶應義塾 スチルベン化合物を有効成分とする角結膜疾患又は老視の予防及び／又は治療のための医薬組成物
WO2018052019A1 (ja) * 2016-09-13 2018-03-22 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
JP2018078860A (ja) * 2016-11-18 2018-05-24 学校法人大阪医科薬科大学 経口組成物
JP2019534335A (ja) * 2016-11-14 2019-11-28 ミングゥ・ワン 眼表面疾患の治療のための製剤および関連方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
WO2005069998A2 (en) * 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
US7522995B2 (en) 2004-02-05 2009-04-21 Nortrup Edward H Method and system for providing travel time information
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006094235A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
EP2007366A2 (en) * 2006-03-24 2008-12-31 Charles H. CELLA Animal product enrichment using resveratrol
US8828966B2 (en) * 2006-10-03 2014-09-09 Claire Mitchell Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
EP2124985A4 (en) * 2007-01-26 2011-06-08 Univ Washington METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
USRE47045E1 (en) * 2007-09-12 2018-09-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
BRPI0912356A2 (pt) 2008-05-01 2015-10-06 Sirtris Pharmaceuticals Inc compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
WO2010037129A1 (en) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals Inc. Quinazolinone, quinolone and related analogs as sirtuin modulators
CA2779303A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
US20110105990A1 (en) * 2009-11-04 2011-05-05 Silvestrini Thomas A Zonal drug delivery device and method
US9125858B2 (en) 2009-11-30 2015-09-08 Wilmore Labs L.L.C. Compositions and methods relating to resveratrol
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
WO2012008549A1 (ja) 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2012149278A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Sustained release latanoprost implant
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
PL2968306T3 (pl) 2013-03-15 2024-01-29 Washington University Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
ES2673942B1 (es) * 2016-11-23 2019-04-09 Consejo Superior Investigacion Compuestos acilados para el tratamiento de patologias oculares
CA3046668A1 (en) * 2017-01-03 2018-07-12 Vitrean, Inc. Methods and devices for treating a retinal detachment
WO2019108875A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating glaucoma

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US6028111A (en) * 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
JP2002503212A (ja) * 1996-10-16 2002-01-29 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 単環式ヌクレオシド、その類似体および使用
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
ATE359785T1 (de) * 1997-07-31 2007-05-15 Kos Life Sciences Inc Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
US7718694B2 (en) * 1997-10-16 2010-05-18 Children's Hospital & Research Center At Oakland Compositions and methods for therapy for diseases characterized by defective chloride transport
US6008260A (en) * 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6028099A (en) * 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
WO2001041806A1 (en) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
MXPA03007609A (es) * 2001-02-27 2004-06-30 Univ Michigan Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico.
US6716596B2 (en) * 2001-03-12 2004-04-06 The Regents Of The University Of California Agents for replacement of NAD+/NADH system in enzymatic reactions
CN101310771B (zh) * 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
CA2462272A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2004253579B2 (en) * 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
CA2555675A1 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
ES2663226T3 (es) * 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
WO2006007411A2 (en) * 2004-06-16 2006-01-19 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006278504B2 (en) * 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2670927T3 (es) * 2005-11-18 2018-06-04 Cornell Research Foundation, Inc. Composiciones de nicotinoil ribósido y métodos de uso
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
CN102388054B (zh) * 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542296A (ja) * 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置
JP2015187141A (ja) * 2005-07-01 2015-10-29 プレジデント アンド フェローズ オブ ハーバード カレッジ 肥満及びインシュリン耐性障害を治療又は予防するための組成物
KR20140048212A (ko) 2011-06-29 2014-04-23 가부시키가이샤 롯데 눈 피로 억제 조성물 및 그것을 함유하는 음식품
JP2013237618A (ja) * 2012-05-11 2013-11-28 Hinoki Shinyaku Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤
JP2016050172A (ja) * 2014-08-28 2016-04-11 学校法人昭和大学 新規スチルベン誘導体
JPWO2016031869A1 (ja) * 2014-08-28 2017-06-15 学校法人慶應義塾 スチルベン化合物を有効成分とする角結膜疾患又は老視の予防及び／又は治療のための医薬組成物
WO2016171152A1 (ja) * 2015-04-20 2016-10-27 学校法人 慶應義塾 角膜障害の治療剤、改善剤または予防剤
WO2018052019A1 (ja) * 2016-09-13 2018-03-22 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
JPWO2018052019A1 (ja) * 2016-09-13 2019-06-24 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
US10898738B2 (en) 2016-09-13 2021-01-26 Megumi Tanaka Visual function printing agent, and method for improving visual functions
JP2019534335A (ja) * 2016-11-14 2019-11-28 ミングゥ・ワン 眼表面疾患の治療のための製剤および関連方法
JP2018078860A (ja) * 2016-11-18 2018-05-24 学校法人大阪医科薬科大学 経口組成物

Also Published As

Publication number Publication date
WO2006105403A3 (en) 2007-03-15
EP1863462A2 (en) 2007-12-12
AU2006230478B2 (en) 2011-12-22
US20070014833A1 (en) 2007-01-18
WO2006105403A2 (en) 2006-10-05
AU2006230478A1 (en) 2006-10-05
CA2603009A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AU2006230478B2 (en) Treatment of eye disorders with sirtuin modulators
JP2008542296A (ja) サーチュイン活性化剤による眼障害の処置
US20060292099A1 (en) Treatment of eye disorders with sirtuin modulators
JP7455917B2 (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
Adelli et al. Development of a Δ9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability
TWI709410B (zh) 具有生物活性親脂性化合物之聚乙二醇化脂質奈米粒子
EP1718568B1 (en) Process for preparing water soluble diterpenes and their applications
KR20060127043A (ko) 녹내장성 망막병증 및 시각신경병증의 치료용 약제
Sharma et al. Application of Vitamin E TPGS in ocular therapeutics–Attributes beyond excipient
WO2020145364A1 (ja) 網膜疾患の治療のための眼内または経口投与用医薬組成物
US20190142740A1 (en) Methods of Eye Treatment Using Therapeutic Compositions Containing Dipyridamole
EP2170343A1 (en) Treatment of age-related macular degeneration
JP4820170B2 (ja) 虚血性神経障害治療又は予防剤
TW202227042A (zh) 雙重鎮痛／消炎組合物、組合及其使用方法
JP5087242B2 (ja) ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム
Cetin A review on ophthalmic delivery systems containing flavonoids for the treatment of eye diseases
Alaimo et al. Chitosan-based nanosuspensions for ocular diagnosis and therapy
JP2025522657A (ja) リファマイシン眼科用組成物およびその使用
EP4611740A1 (en) Cannabinoid formulations and use for treatment of emotional disorders and sexual dysfunction
US20230405024A1 (en) Novel nano-formulation of cannabidiol (cbd) and other cannabinoids for treatment of ocular disorders
HK1098450B (en) Process for preparing water soluble diterpenes and their applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111216

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120402

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120508